FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula (I), where m equals 1-2, and each R1 (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, hydroxy-(2-6C)alkoxy, amino-(2- 6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di[(1-6C)alkyl]amino-(1-6C)alkyl, hydroxy-(2-6C)alkylamino, halogen-(2-6C)alkylamino, amino-(2-6C)alkylamino, (1-6C)alkoxy-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino, heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy and heterocyclylamino, where heterocyclyl is a 3-7-member monocyclic saturated ring containing one or two heteroatoms selected from nitrogen, oxygen and sulphur, wherein the heterocyclyl can have 1-2 substitutes defined in claim 1, and any of the substitutes R1 given above, which contains a CH3 group bonded to a carbon or nitrogen atom, can contain a substitute given in claim 1, R2 is a halogen, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, and R4 is hydroxy, (1-6C)alkyl or (1-6C)alkoxy; or pharmaceutically acceptable salts thereof. The invention also relates to methods for synthesis of said compounds, pharmaceutical compositions based on said compounds, and use of said compounds in treating diseases or medical conditions mediated by cytokines.
EFFECT: more effective use of the compounds.
13 cl, 8 tbl, 15 ex
Authors
Dates
2011-08-27—Published
2006-08-07—Filed